Form 4: HCA Healthcare CEO Sells Shares Under 10b5-1 Plan

HCA Healthcare CEO Samuel N. Hazen reported the sale of over 42,000 shares and a trust transfer of 1,045 shares, all executed under a pre-arranged 10b5-1 trading plan.

Summary

• HCA Healthcare CEO Samuel N. Hazen reported multiple transactions involving the company's common stock.
• On February 3, 2026, Hazen sold a total of 42,877 shares of common stock in several transactions.
• The sales occurred at weighted average prices ranging from $497.1783 to $502.9482 per share.
• On February 4, 2026, Hazen transferred 1,045 shares of common stock to a trust at a price of $498.35 per share, which was a change in the form of beneficial ownership and did not alter his total beneficial ownership.
• All reported transactions were made pursuant to a Rule 10b5-1(c) trading plan.
• Following these transactions, Hazen directly owns 31,231 shares and indirectly owns 1,317,452 shares through various trusts and an LP.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be a negative signal, the execution under a 10b5-1 plan indicates these were pre-scheduled transactions, mitigating concerns about opportunistic selling based on new information.

Positives

• Transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan, indicating they were not based on new, non-public information.

Negatives

• The CEO sold a significant number of shares (42,877 shares), which could be perceived as a reduction in direct exposure to the company's stock.

Future Outlook

NA

Management Comments

• The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• The Reporting Person believes that the transfer of shares to the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those by top executives like a CEO, are closely watched by investors for signals about management's confidence in the company's future. However, transactions executed under a Rule 10b5-1 plan are generally viewed as less indicative of future performance as they are pre-scheduled and not based on immediate, non-public information.

Related Party Transactions

• Transfer of 1,045 shares to a trust (HD Trust) on February 4, 2026, in exchange for assets of equal value. This is a transaction with an entity indirectly controlled by the reporting person.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO could be interpreted differently by investors, but the 10b5-1 plan context generally reduces negative sentiment. The overall beneficial ownership remains substantial.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Key Dates

Recommendation

The filing details routine insider transactions under a pre-arranged 10b5-1 plan, which are generally not considered a strong indicator for future stock performance. While there was a sale of shares, it was planned, and the CEO retains significant beneficial ownership. Therefore, this specific filing does not provide new information warranting a change in investment recommendation; a 'hold' stance is appropriate pending broader company or market developments.

Keywords

HCA Healthcare, HCA, Samuel N Hazen, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Healthcare Stock